NextCure Inc

NXTC

Company Profile

  • Business description

    NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.

  • Contact

    9000 Virginia Manor Road
    Suite 200
    BeltsvilleMD20705
    USA

    T: +1 240 399-4900

    https://www.nextcure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    43

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.4015.50-0.18%
CAC 407,712.6316.360.21%
DAX 4023,960.52173.070.73%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,836.1913.280.15%
HKSE23,887.8328.23-0.12%
NASDAQ20,601.10207.971.02%
Nikkei 22539,587.68223.20-0.56%
NZX 50 Index12,764.951.65-0.01%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,589.3013.70-0.16%
SSE Composite Index3,473.130.810.02%

Market Movers